Comparison of Oxcarbazepine and Carbamazepine in the treatment of Trigeminal Neuralgia: a systematic review and meta-analysis
Authors:
- Cristian MendietaCMCristian Mendieta
- Marina Barbosa Da SilvaMSMarina Barbosa Da Silva
- Livia Aguiar Nogueira-RosaLNLivia Aguiar Nogueira-Rosa
- Domênica Baroni Coelho de Oliveira FerreiraDFDomênica Baroni Coelho de Oliveira Ferreira
- Jhon Bocanegra-BecerraJBJhon Bocanegra-Becerra
- Nathalia Moraes FigueiredoNFNathalia Moraes Figueiredo
Preprint
- 27 September 2024
- preprint
- Published by Springer Nature in Research Square
Abstract
Oxcarbazepine (OXC) has demonstrated comparable efficacy to Carbamazepine (CBZ) in the treatment of Trigeminal neuralgia (TN), with the added benefit of fewer adverse events (AEs). Whether it can be used as a substitute for carbamazepine is yet to be verified. To address this, we conducted a comprehensive meta-analysis, exploring efficacy and adverse events in detail. We searched PubMed, Embase, Cochrane Library, and Google Scholar for studies comparing CBZ to OXC in patients with TN. The main outcomes were efficacy, AEs, frequency of neurological AEs, skin reactions, and alterations in laboratory parameters. Statistical analysis was performed using Review Manager 5.4.1. And the risk of bias was assessed using RoB-2 and ROBINS-I. We included 838 patients from three observational studies and two randomized clinical trials (RCTs). CBZ was used to treat TN in 445 (53.1%) patients. The CBZ group when compared with the OXC group had no significant difference in efficacy (OR:0.58; 95% Cl:0.14-2.40; p=0.45). Both groups had significant differences noted in AEs, with higher frequency observed in the CBZ group (OR:2.30; 95% Cl:1.49-3.54; p=0.0002). Similarly, there was a significant difference in neurological AEs (OR:2.76; 95% Cl:1.53-4.87; p=0.0007). OXC and CBZ demonstrated similar efficacy in treating trigeminal neuralgia. However, the consideration of adverse events may favor clinical decision-making to OXC due to its superiority. Nonetheless, more randomized controlled trials (RCTs) are necessary to confirm this conclusion in the futureKeywords
All Related Versions
This publication has 21 references indexed in Scilit:
- Real‐world effectiveness and tolerability of carbamazepine and oxcarbazepine in 354 patients with trigeminal neuralgiaEuropean journal of pain, 2021
- Rashes and other hypersensitivity reactions associated with antiepileptic drugs: A review of current literatureSeizure: European Journal of Epilepsy, 2019
- European Academy of Neurology guideline on trigeminal neuralgiaEuropean Journal of Neurology, 2019
- Adverse effects of anti-epileptics in trigeminal neuralgiform painActa Neurologica Scandinavica, 2018
- Efficacy and Tolerability of Antiepileptic Drugs in Patients with Focal Epilepsy: Systematic Review and Network Meta‐analysesPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2016
- Prevalence of trigeminal neuralgiaThe Journal of the American Dental Association, 2016
- Oxcarbazepine monotherapy in carbamazepine-unresponsive trigeminal neuralgiaJournal of Clinical Neuroscience, 2008
- What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs?Epilepsy & Behavior, 2004
- Clinical use of tricyclic anticonvulsants in painful neuropathies and bipolar disordersEpilepsy & Behavior, 2002
- Carbamazepine in the Treatment of NeuralgiaArchives of Neurology, 1968